Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study

References

• Gazit E, Loewenthal R. The immunogenetics of pemphigus vulgaris. Autoimmun Rev. 2005;4:16–20.
   PubMed Web of Science ®Google Scholar
• Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev. 2012;11:226–230.
   PubMed Web of Science ®Google Scholar
• Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405–414.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Gdalevich M, Ziv M, et al. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol. 2014;71:284–292.
   PubMed Web of Science ®Google Scholar
• Atzmony L, Hodak E, Leshem YA, et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:264–271.
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–628.
   PubMed Web of Science ®Google Scholar
• Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128:2745–2747.
   PubMed Web of Science ®Google Scholar
• Qureshi ZP, Magwood JS, Singh S, et al. Rituximab and biosimilars equivalence and reciprocity. Biosimilars. 2013;2013:19–25.
   PubMedGoogle Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–1779.
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–2040.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM494010.pdf
   Google Scholar
• Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27:1285–1292.
   PubMed Web of Science ®Google Scholar
• Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–908.
   PubMed Web of Science ®Google Scholar
• Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;(1):CD006263.
   PubMed Web of Science ®Google Scholar
• Salarvand F, Fatehi Z, Shahali M, et al. Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran: a multiple cross-sectional study. Dermatol Ther. 2019;32:e12827.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14:323–331.
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138.
   PubMed Web of Science ®Google Scholar
• Schmidt E. Rituximab as first-line treatment of pemphigus. Lancet. 2017;389:1956–1958.
   PubMed Web of Science ®Google Scholar
• Sanchez J, Ingen-Housz-Oro S, Chosidow O, et al. Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus. JAMA Dermatol. 2018;154:363–365.
   PubMed Web of Science ®Google Scholar
• Leshem YA, David M, Hodak E, et al. A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab. Arch Dermatol Res. 2014;306:67–74.
   PubMed Web of Science ®Google Scholar
• Cho HH, Jin SP, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2014;28:186–191.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10:727–732.
   PubMed Web of Science ®Google Scholar
• Cho YT, Lee FY, Chu CY, et al. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94:472–473.
   PubMed Web of Science ®Google Scholar
• Bohlega S, Al-Shammri S, Al Sharoqi I, et al. Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin. 2008;24:2897–2903.
   PubMed Web of Science ®Google Scholar
• Cheraghali AM. Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. Daru. 2012;20:35.
   PubMed Web of Science ®Google Scholar
• Patil S, Sharma N, Godse K, et al. Biosimilars in pemphigus vulgaris. Indian J Dermatol. 2014;59:416–418.
   PubMed Web of Science ®Google Scholar
• Toogeh G, Faranoush M, Razavi SM, et al. A double-blind, randomized comparison study between Zytux TM vs MabThera® in treatment of CLL with FCR regimen: non-inferiority clinical trial. Int J Hematol Oncol Stem Cell Res. 2018;12:84–91.
   PubMedGoogle Scholar
• Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
   PubMedGoogle Scholar
• Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150:703–708.
   PubMed Web of Science ®Google Scholar
• Balighi K, Daneshpazhooh M, Mahmoudi H, et al. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res. 2019;311:63–69.
   PubMed Web of Science ®Google Scholar
• Balighi K, Daneshpazhooh M, Akbari Z, et al. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. J Dermatolog Treat. 2018;12:1–4.
   Google Scholar
• Cho SI, Kim JW, Lim JS, et al. Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab. Dermatol Ther. 2019;8:e12814.
   Google Scholar
• Balighi K, Sakhi RS, Daneshpazhooh M, et al. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. 2018;31:e12671.
   PubMed Web of Science ®Google Scholar
• Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79:97–103.
   PubMed Web of Science ®Google Scholar
• Hebert V, Joly P. Rituximab in pemphigus. Immunotherapy. 2018;10:27–37.
   PubMed Web of Science ®Google Scholar
• Feldman RJ. Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol. 2015;173:858–859.
   PubMed Web of Science ®Google Scholar
• Mahmoudi H, Balighi K, Tavakolpour S, et al. Unexpected worsening of pemphigus vulgaris after rituximab: a report of three cases. Int Immunopharmacol. 2019;71:40–42.
   PubMed Web of Science ®Google Scholar
• Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129:2404–2410.
   PubMed Web of Science ®Google Scholar
• Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. JAMA Dermatol. 2014;150:266–272.
   PubMed Web of Science ®Google Scholar
• Iranzo P, Pigem R, Giavedoni P, et al. Remission time after rituximab treatment for autoimmune bullous disease: a proposed update definition. Skin Pharmacol Physiol. 2015;28:255–256.
   PubMed Web of Science ®Google Scholar